Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
about
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.The role of IL-17 in the treatment of psoriatic arthritis.Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.
P2860
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Treatment outcomes with ixekiz ...... Phase III randomized studies.
@en
Treatment outcomes with ixekiz ...... Phase III randomized studies.
@nl
type
label
Treatment outcomes with ixekiz ...... Phase III randomized studies.
@en
Treatment outcomes with ixekiz ...... Phase III randomized studies.
@nl
prefLabel
Treatment outcomes with ixekiz ...... Phase III randomized studies.
@en
Treatment outcomes with ixekiz ...... Phase III randomized studies.
@nl
P2093
P2860
P356
P1476
Treatment outcomes with ixekiz ...... o Phase III randomized studies
@en
P2093
A B Gottlieb
J Erickson
L Mallbris
P2860
P304
P356
10.1111/JDV.13990
P577
2016-11-02T00:00:00Z